Very nice results, but psoriasis is a smaller market than you'd think (OOM comparable to MF with no real chance of an undiagnosed potential add-on). Patients WILL push hard for aggressive treatment (I have known two people who died from side effects of high dose steroids used mostly to treat psoriasis). No hints of safety issues, but the trial was short.
I can see a big overall market for the JAK1 selective agents, but I don't presently see an on-ramp to the FDA fast track. That's at least a 6-month difference in time-to-market.
My take on management statements is that the potential jackpot is in IBD, but that's a rapidly moving target. At least for Crohn's disease, immunologists are excited (and I mean REALLY excited) about the possibility of an outright cure. We've seen that sort of excitement before, and it is often exaggerated (recall angiogenesis inhibitors, recall association of H. pylori with ulcers) Still, a JAK1 drug is going to be among a crowd of hunters for that prize.